Merck & Co Inc (LTS:0QAH)
$ 131.3 0 (0%) Market Cap: 249.37 Bil Enterprise Value: 272.91 Bil PE Ratio: 20.67 PB Ratio: 5.61 GF Score: 81/100

Merck & Co Inc at ASCO Annual Meeting Transcript

Jun 07, 2022 / 12:00PM GMT
Release Date Price: $90.23 (+0.03%)
Editor

This transcript is incomplete due to a portion of the audio being unavailable. The following summary is not a verbatim representation of this missing audio portion and has been provided by the Company.

Peter Dannenbaum
Merck & Co., Inc. - VP of IR

[Good morning. I am Peter Dannenbaum, head of investor relations. Welcome to Merck's ASCO investor event. Thank you for joining us today, both those here in the room in Chicago and those on the webcast.

Presenting from Merck today are Dr. Dean Li, President of Merck Research Labs; Dr. Eliav Barr, Head of Global Clinical Development and Chief Medical Officer; Dr. Eric Rubin, Head of Early-Stage Oncology Clinical Development; and Jannie Oosthuizen, President of U.S. Human Health.

Our agenda includes roughly 30 minutes of upfront remarks, followed by 30 minutes of Q&A. Those tuning in virtually can submit questions via the webcast or e-mail me directly at [email protected].

Joining for the Q&A session will be Dr. Scot Ebbinghaus and Dr. Greg Lubinecki from our Oncology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot